Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): A study to determine the effect of a structured SMBG intervention

Marina Scavini, Emanuele Bosi, Antonio Ceriello, Francesco Giorgino, Massimo Porta, Antonio Tiengo, Giacomo Vespasiani, Davide Bottalico, Raffaele Marino, Christopher Parkin, Erminio Bonizzoni, Domenico Cucinotta

Research output: Contribution to journalArticle

Abstract

Self-monitoring of blood glucose (SMBG) is a core component of diabetes management. However, the International Diabetes Federation recommends that SMBG be performed in a structured manner and that the data are accurately interpreted and used to take appropriate therapeutic actions. We designed a study to evaluate the impact of structured SMBG on glycemic control in non-insulin-treated type 2 diabetes (T2DM) patients. The Prospective, Randomized Trial on Intensive SMBG Management Added Value in Non-insulin-Treated T2DM Patients (PRISMA) is a 12-month, prospective, multicenter, open, parallel group, randomized, and controlled trial to evaluate the added value of an intensive, structured SMBG regimen in T2DM patients treated with oral agents and/or diet. One thousand patients (500 per arm) will be enrolled at 39 clinical sites in Italy. Eligible patients will be randomized to the intensive structured monitoring (ISM) group or the active control (AC) group, with a glycosylated hemoglobin (HbA1c) target of

Original languageEnglish
Pages (from-to)663-672
Number of pages10
JournalActa Diabetologica
Volume50
Issue number5
DOIs
Publication statusPublished - 2013

Keywords

  • Diabetes medication algorithm
  • Patient empowerment
  • Randomized clinical trial
  • Self-monitoring of blood glucose
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): A study to determine the effect of a structured SMBG intervention'. Together they form a unique fingerprint.

  • Cite this